HopeStage
Back to all studies
CompletedNCT00235274

Secretin and information processing in schizophrenia

About this titleRead the official source — NCT00235274
Medication studyAges 18–55United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations
IndianapolisSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2005
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
Indiana University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT00235274
Official title
Show the full official title

Effects of RG1068 (Secretin) on Information Processing in Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Indianapolis

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Indiana University, a university.

Did this study involve medication?

Yes. The study involved medication, including Subcutaneous Secretin.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies